RenovoRx’s Two-Track Strategy: Device Sales Fund a Pancreatic Cancer Moonshot

MOUNTAIN VIEW, CA – June 04, 2026 – When RenovoRx CEO Shaun Bagai steps into the virtual spotlight at the iAccess Alpha investment conference on June 23rd, he’ll be presenting more than just a standard corporate update. He’ll be outlining a case study in modern biotech strategy: a company simultaneously executing a pragmatic commercial rollout while pursuing a high-risk, high-reward clinical moonshot. This dual-track approach is a piece of operational innovation that sets RenovoRx apart in a field often characterized by all-or-nothing binary outcomes.

The company is building a solid financial foundation through the growing sales of its FDA-cleared RenovoCath® drug-delivery device. At the same time, it is on the cusp of completing enrollment for a pivotal Phase III trial targeting one of oncology’s most formidable foes: locally advanced pancreatic cancer (LAPC). It’s a strategy designed to generate revenue and validation today while chasing a multi-billion dollar market opportunity tomorrow.

The Commercial Engine: RenovoCath's Market Ascent

For many small-cap life sciences companies, the period between inception and a potential blockbuster drug approval is known as the “valley of death,” marked by high cash burn and reliance on dilutive financing. RenovoRx is charting a different course by actively commercializing its core technology—the RenovoCath device—as a standalone product.

The strategy is paying off. The company posted a record $563,000 in revenue for the first quarter of 2026, a staggering 136% increase over the previous quarter. This performance puts RenovoRx well on its way to surpassing its 2025 full-year revenue of $1.1 million, prompting the company to reiterate its 2026 guidance of $3-$4 million. This isn't just a rounding error; it's the sound of a commercial engine starting to hum.

This growth is fueled by what the company describes as “accelerating adoption at high-volume cancer centers.” As of May 2026, 16 cancer centers are actively using RenovoCath, with another 32 in the pipeline. Crucially, these include prestigious National Cancer Institute (NCI)-designated centers, which serve as key opinion leaders in the oncology community. Each new order from an NCI center not only adds to the top line but also provides powerful third-party validation of the technology’s utility.

RenovoCath enables a procedure called Trans-Arterial Micro-Perfusion (TAMP™), which allows physicians to isolate a specific artery feeding a tumor and deliver chemotherapy directly to the target. This localized approach aims to maximize the drug concentration at the tumor site while minimizing the debilitating systemic toxicities associated with conventional intravenous chemotherapy. By selling the device for its currently cleared indications—which include targeted drug infusion—RenovoRx is building a base of clinical users who are becoming experts in the TAMP procedure. This creates a pre-built network of proficient physicians ready to adopt the company's future drug-device combination therapies, should they be approved.

A New Frontier Against a Formidable Foe

While device sales provide the financial ballast, the company’s ultimate ambition lies in its TIGeR-PaC clinical trial. The study is evaluating a drug-device combination product: the standard-of-care chemotherapy drug gemcitabine delivered intra-arterially (IAG) via the RenovoCath device to treat locally advanced pancreatic cancer. LAPC is a notoriously aggressive and difficult-to-treat disease where the tumor has grown outside the pancreas, encasing major blood vessels and making it unresectable.

RenovoRx is set to hit a critical milestone, expecting to complete enrollment for the Phase III trial by the end of June 2026. With the trial already 93% enrolled as of the first quarter, this final step will start the clock toward a final data readout anticipated in mid-to-late 2027. For patients and clinicians desperate for new options, this timeline is a beacon of hope.

The potential of the TAMP platform in this setting is significant. “By delivering chemotherapy directly across the arterial wall into the tumor, you have the potential to achieve a much higher drug concentration where it matters most, without poisoning the rest of the body,” explained one interventional oncologist not affiliated with the company. “For a fragile patient population like those with LAPC, minimizing toxicity is just as important as maximizing efficacy.”

Success in TIGeR-PaC would not only be a landmark achievement in pancreatic cancer treatment but would also validate the entire TAMP platform, opening the door for its application with other drugs and in other solid tumors.

Building a Strategic Fortress

Beyond its dual commercial and clinical progress, RenovoRx has been methodically building a strategic fortress to protect its innovations and enhance shareholder value. A key component of this is its success in securing regulatory advantages. The company recently announced its third FDA Orphan Drug Designation (ODD), this time for the use of the chemotherapy drug oxaliplatin in pancreatic cancer. This follows previous ODDs for its IAG combination in both pancreatic and bile duct cancer.

ODD is granted to therapies for rare diseases and provides powerful incentives, including seven years of market exclusivity upon FDA approval. For a company like RenovoRx, this exclusivity is a critical asset, creating a long runway to establish a market and recoup R&D investment without immediate generic competition.

This regulatory acumen is matched by prudent financial management. A private placement in March 2026 raised approximately $10 million in gross proceeds, strengthening the balance sheet. With $12.4 million in cash as of March 31, 2026, management is confident it has a cash runway to fund operations into at least the second half of 2027—a timeline that strategically aligns with the expected data readout from the TIGeR-PaC trial.

As Shaun Bagai prepares for his investor presentation, he will be detailing a company that is firing on multiple cylinders. The operational innovation lies in the synergy of its strategy: device sales are not just generating revenue, but also de-risking the business, building a commercial infrastructure, and funding the very research that could transform the company into a major player in oncology. This two-track approach provides multiple paths to value creation, making RenovoRx a compelling case study for investors and a company to watch in the evolving landscape of cancer therapy.